{"id":15868,"date":"2012-11-24T00:10:00","date_gmt":"2012-11-23T23:10:00","guid":{"rendered":"http:\/\/www.fedaiisf.it\/generico-del-lipitor-richiamato-ranbaxy-inciampa-ancora\/"},"modified":"2012-11-24T00:10:00","modified_gmt":"2012-11-23T23:10:00","slug":"generico-del-lipitor-richiamato-ranbaxy-inciampa-ancora","status":"publish","type":"post","link":"https:\/\/www.fedaiisf.it\/en\/generico-del-lipitor-richiamato-ranbaxy-inciampa-ancora\/","title":{"rendered":"Generic of the recalled Lipitor, Ranbaxy stumbles again."},"content":{"rendered":"<p style=\"text-align: center\"><span style=\"font-size: xx-large\"><a href=\"http:\/\/www.pharmalot.com\/2012\/11\/ranbaxy-stumbles-again-generic-lipitor-is-recalled\/#comments\" target=\"_blank\" rel=\"noopener\"><strong><span id=\"result_box\" lang=\"it\"><span title=\"Ranbaxy Stumbles Again: Generic Lipitor Is Recalled\">Ranbaxy stumbles again: <br \/> Generic Lipitor is Recalled<\/span><\/span><\/strong><\/a><\/span><span id=\"result_box\" lang=\"it\"><span title=\"Ranbaxy Stumbles Again: Generic Lipitor Is Recalled\"><br \/> <\/span><span title=\"Make a comment\">http:\/\/www.pharmalot.com\/2012\/11\/ranbaxy-stumbles-again-generic-lipitor-is-recalled\/#comments<br \/> <\/span><\/span><\/p>\n<p style=\"text-align: left\"><span id=\"result_box\" lang=\"it\"><span title=\"By Ed Silverman \/\/ November 23rd, 2012 \/\/ 5:27pm\">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<span style=\"font-size: small\"><strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; By Ed Silverman \/ Nov 23, 2012 \/ 5:27pm<\/strong><\/span><br \/> <\/span><em><span title=\"By Ed Silverman \/\/ November 23rd, 2012 \/\/ 5:27pm\"><br \/> <\/span><span style=\"font-size: medium\"><span title=\"Will Ranbaxy Laboratories ever get it right?\">Will Ranbaxy Laboratories ever get it right? <\/span><span title=\"Late last week, the troubled drugmaker recalled more than three dozen lots of generic Lipitor because some may contain tiny glass particles.\">Last week, the troubled drugmaker recalled more than three dozen lots of generic Lipitor because some may contain glass particles. <\/span><span title=\"The move is only the latest in a series of quality-control gaffes that, at one point, led the FDA to ban imports of 30 of its medicines (back story).\">The move is just the latest in a series of quality control gaffes that, at one point, led the FDA to ban imports of 30 of its drugs.<\/p>\n<p> <\/span><span title=\"The recall involves 10mg, 20mg and 40mg doses, but not the 80mg dosage and the drugmaker says the move is being made \u201cproactively,\u201d \u201cout of an abundance of caution, and in keeping the safety of our customers in mind.\u201d The recall\">The recall involves 10mg, 20mg and 40mg doses, but not the 80mg dosage and the pharmaceutical company says the move has been made &quot;proactive&quot;, &quot;out of an excess of precaution, and in maintaining the safety of our customers.&quot; The recall <\/span><span title=\"is also \u201cbeing conducted with the full knowledge of the US FDA,\u201d according to a statement on the web site of the Ranbaxy US subsidiary (see more here).\">it is also &quot;underway with the full knowledge of the U.S. FDA,&quot; according to a statement on U.S. subsidiary Ranbaxy&#039;s website.<\/p>\n<p> <\/span><span title=\"This comes at a delicate time for Ranbaxy, which in January signed a consent decree for a permanent injunction that prevents the Indian drugmaker from making medicines for the US market until certain facilities meet US standards (read here).\">This comes at a very delicate moment for Ranbaxy, which in January signed an authorization decree for a permanent injunction that prevents the Indian pharmaceutical company from making drugs for the US market until some plants comply with US standards. <\/span><span","protected":false},"excerpt":{"rendered":"<p>Ranbaxy inciampa ancora: Lipitor Generico &egrave; Richiamato http:\/\/www.pharmalot.com\/2012\/11\/ranbaxy-stumbles-again-generic-lipitor-is-recalled\/#comments &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Di Ed Silverman \/&nbsp; 23 Nov 2012 \/&nbsp; 17:27 Will Ranbaxy Laboratories lo far&agrave; mai bene? La scorsa settimana, la travagliata casa farmaceutica&nbsp; ha richiamato pi&ugrave; di tre dozzine di lotti di Lipitor generico perch&eacute; alcuni possono contenere particelle di vetro. La mossa &egrave; solo l&#8217;ultima &hellip;<\/p>","protected":false},"author":1,"featured_media":9846,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[90],"tags":[],"class_list":["post-15868","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-fedaiisf-archivio-storico"],"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/15868","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/comments?post=15868"}],"version-history":[{"count":0,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/15868\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media\/9846"}],"wp:attachment":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media?parent=15868"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/categories?post=15868"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/tags?post=15868"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}